Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup study |
| |
Authors: | Shoji Nagao Shin Nishio Hirofumi Michimae Hiroshi Tanabe Satoshi Okada Takeo Otsuki Maki Tanioka Keiichi Fujiwara Mitsuaki Suzuki Junzo Kigawa |
| |
Institution: | 1. Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi 673-8558, Japan;2. Department of Obstetrics and Gynecology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Japan;3. Department of Clinical Medicine (Biostatistics and Pharmaceutical Medicine), School of Pharmacy, Kitasato University, 5-9-1 Shirogane, Minato-ku, Tokyo, Japan;4. Department of Obstetrics and Gynecology, Jikei University Kashiwa Hospital, 163-1 Kashiwasita, Kashiwa, Japan;5. Department of Obstetrics and Gynecology, Tsukuba University, 1-1-1 Tennodai, Tsukuba, Japan;6. Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Japan;g Department of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi, Japan;h Department of Gynecologic Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka-city 350-1241, Japan;i Department of Obstetrics and Gynecology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Japan;j Matsue City Hospital, 32-1 Noshiro-cho, Matsue 690-8509, Japan |
| |
Abstract: | ObjectiveThe concept of “platinum sensitivity” has been widely applied in the management of recurrent ovarian cancer. This study aimed to evaluate the applicability of this concept to recurrent endometrial cancer.Patients and methodsIn this multicenter retrospective cohort study, the clinical data of patients with recurrent endometrial cancer, who had a history of receiving first-line platinum-based chemotherapy and who received second-line platinum-based chemotherapy at the time of recurrence between January 2005 and December 2009 were reviewed.ResultsA total of 262 patients from 30 centers with initial FIGO stage classifications of I (29), II (23), III (122), and IV (88) were enrolled. In total, 153 endometrioid adenocarcinomas, 34 serous adenocarcinomas, 17 clear cell adenocarcinomas, 36 carcinosarcomas, and 22 “other” tumors were documented. The response rates for patients with platinum-free intervals of < 6 months, 6–11 months, 12–23 months, and ≥ 24 months were 25%, 38%, 61%, and 65%, respectively. The median progression-free survival after second-line platinum-based chemotherapy for patients with platinum-free intervals of < 12 months and ≥ 12 months was 4.4 (95% confidence interval (CI) = 3.7–5.8) months and 10.3 (95% CI = 8.2–12.6) months, respectively (log-rank P < 0.0001), and the median overall survival was 13.8 (95% CI = 10.6–18.1) months and 40.9 (95% CI = 25.3–54.2) months, respectively (log-rank P < 0.0001).ConclusionPlatinum-free interval is a predictor of response and survival after second-line platinum-based chemotherapy in patients with recurrent endometrial cancer. The concept of “platinum sensitivity” could be applicable to recurrent endometrial cancer. |
| |
Keywords: | Recurrent endometrial cancer Platinum sensitivity Second-line chemotherapy Platinum-based chemotherapy |
本文献已被 ScienceDirect 等数据库收录! |
|